Should You Buy TScan Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, TScan Therapeutics, Inc. (TCRX) carries a solid Quality of Company rating of 6.3/10. Trading at $0.32, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 2 of 2 CirclFi valuation models project upside for TScan Therapeutics, Inc. (TCRX) at $0.32 — the model consensus leans bullish, with a Quality Score of 6.3/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for TScan Therapeutics, Inc. (TCRX) in 2026?
What Is the Bull Case vs the Bear Case for TScan Therapeutics, Inc. (TCRX)?
| Bull case — $1.88 target (+484.7%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 2 of 2 models identify upside from $0.32 to a median fair value of $1.79, indicating the market hasn't fully priced in TScan Therapeutics, Inc.'s earnings power. | No active model flags significant downside for TCRX. The low Value Trap score paints a constructive picture. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $1.88 (+484.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: gene therapy and cell therapy innovation could provide meaningful support for TScan Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does TCRX Compare to Its Biotechnology Peers?
Valuation data pages: STRO · ASMB · HRTX · QURE · TRAW · CTMX · CRBU · DSGN · HURA · EXEL · INCY
Which Other Stocks Score Like TCRX on Quality?
Closest companies to TCRX’s Quality of Company score of 6.3/10, across all industries.
Which Biotechnology Screens Does TCRX Appear In?
So Is TScan Therapeutics, Inc. (TCRX) Worth Buying in 2026?
TScan Therapeutics, Inc. at $0.32 presents what our engine identifies as a high-conviction opportunity: 2 of 2 models see upside, quality stands at 6.3/10, and the median fair value of $1.79 implies +456.1% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. TScan Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TCRX Stock?
Should I buy TCRX stock right now?
Based on CirclFi's multi-model analysis, 2 of 2 models see upside for TCRX at $0.32. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in TScan Therapeutics, Inc.?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does TCRX compare to its competitors?
Among Biotechnology peers, TCRX holds a Quality Score of 6.3/10. Comparable companies include STRO (QOC 6.4), ASMB (QOC 6.3), HRTX (QOC 6.4). The relative ranking helps investors identify whether TCRX offers better fundamental quality than alternatives in the same sector.
Is TCRX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TCRX's Quality Score of 6.3/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy TCRX at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $1.70 to $1.88. At $0.32, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TCRX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad